Treatment Approach for Undifferentiated CTD with NSIP Pattern

Guideline-Recommended Treatment Hierarchy

The American College of Rheumatology recommends mycophenolate as the preferred first-line treatment option for undifferentiated CTD with NSIP pattern, with rituximab reserved as an alternative first-line option or for progressive disease 1, 2
Mycophenolate is conditionally recommended as the preferred first-line treatment option across all systemic autoimmune rheumatic diseases with ILD, including undifferentiated CTD, according to the American College of Rheumatology 1, 2
Rituximab is conditionally recommended as an alternative first-line option, but ranks after mycophenolate in the treatment hierarchy, as suggested by the American College of Rheumatology 1, 2

For non-progressive or slowly progressive disease, the European League Against Rheumatism recommends starting with mycophenolate monotherapy (2g daily) as the preferred first-line agent 1, 2, 3
Rituximab can be selected instead of mycophenolate if there are specific clinical factors favoring it, such as active inflammatory arthritis in RA-ILD, according to the European League Against Rheumatism 4
Short-term glucocorticoids (≤3 months) may be used as a bridge when initiating therapy, as recommended by the American College of Rheumatology 2, 5

For progressive disease despite first-line therapy, the American College of Rheumatology recommends switching to or adding rituximab if disease progresses on mycophenolate monotherapy 1, 2
Consider adding (not switching to) a second agent while continuing the first-line therapy, as suggested by the American College of Rheumatology 2, 5

For rapidly progressive ILD, the American College of Rheumatology recommends considering dual combination therapy (glucocorticoids plus one immunosuppressant) or even triple therapy depending on severity 2, 5

Pulmonary function tests (FVC and DLCO) should be performed every 3-6 months to assess disease progression, as recommended by the European League Against Rheumatism 4
High-resolution CT should be performed at baseline and annually or with significant PFT changes, according to the European League Against Rheumatism 4
Complete blood count should be performed every 2-4 months for immunosuppression monitoring, as suggested by the European League Against Rheumatism 4